GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Sartorius AG (OTCPK:SOAGY) » Definitions » Total Liabilities

SOAGY (Sartorius AG) Total Liabilities : $6,678 Mil (As of Sep. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Sartorius AG Total Liabilities?

Sartorius AG's Total Liabilities for the quarter that ended in Sep. 2024 was $6,678 Mil.

Sartorius AG's quarterly Total Liabilities declined from Mar. 2024 ($7,466.41 Mil) to Jun. 2024 ($6,600.75 Mil) but then increased from Jun. 2024 ($6,600.75 Mil) to Sep. 2024 ($6,678.02 Mil).

Sartorius AG's annual Total Liabilities increased from Dec. 2021 ($4,494.58 Mil) to Dec. 2022 ($4,575.00 Mil) and increased from Dec. 2022 ($4,575.00 Mil) to Dec. 2023 ($7,631.30 Mil).


Sartorius AG Total Liabilities Historical Data

The historical data trend for Sartorius AG's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sartorius AG Total Liabilities Chart

Sartorius AG Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,972.63 3,776.70 4,494.58 4,575.00 7,631.30

Sartorius AG Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7,701.39 7,631.30 7,466.41 6,600.75 6,678.02

Sartorius AG Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Sartorius AG's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=1450.164+(5477.972+641.548
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+61.614)
=7,631

Total Liabilities=Total Assets (A: Dec. 2023 )-Total Equity (A: Dec. 2023 )
=10638.277-3006.979
=7,631

Sartorius AG's Total Liabilities for the quarter that ended in Sep. 2024 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=1084.351+(4912.542+618.645
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+62.486)
=6,678

Total Liabilities=Total Assets (Q: Sep. 2024 )-Total Equity (Q: Sep. 2024 )
=10870.255-4192.231
=6,678

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sartorius AG Total Liabilities Related Terms

Thank you for viewing the detailed overview of Sartorius AG's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Sartorius AG Business Description

Address
Otto-Brenner-Strasse 20, Gottingen, NI, DEU, 37079
Sartorius AG is a leading provider of bioprocessing solutions. Its Bioprocess division sells equipment and consumables for upstream and downstream manufacturing of biologic drugs, and has a focus on single-use technology, or SUT. Its Lab Products and Services division offers a wide range of products for lab use, including scales, pipettes, and filtration equipment. As of 2022, the Bioprocess and LPS divisions contributed 80% and 20% of revenue, respectively. Bioprocess is housed in its subsidiary Sartorius Stedim Biotech, of which Sartorius AG has a 74% ownership and 85% voting control. The business is geographically diverse, with revenue across Europe, the Middle East, and Africa (37% of 2022 sales), the Americas (37%), and Asia-Pacific (26%). We estimate China revenue to be around 10%.